Cytokines in Pain: Harnessing Endogenous Anti-Inflammatory Signaling for Improved Pain Management
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Current pain therapeutics offer inadequate relief to patients with chronic pain. A growing literature supports that pro-inflammatory cytokine signaling between immune, glial, and neural cells is integral to the development of pathological pain. Modulation of these communications may hold the key to improved pain management. In this review we first offer an overview of the relationships between pro-inflammatory cytokine and chemokine signaling and pathological pain, with a focus on the actions of cytokines and chemokines in communication between glia (astrocytes and microglia), immune cells (macrophages and T cells), and neurons. These interactions will be discussed in relation to both peripheral and central nervous system locations. Several novel non-neuronal drug targets for controlling pain are emerging as highly promising, including non-viral IL-10 gene therapy, which offer the potential for substantial pain relief through localized modulation of targeted cytokine pathways. Preclinical investigation of the mechanisms underlying the success of IL-10 gene therapy revealed the unexpected discovery of the powerful anti-nociceptive anti-inflammatory properties of D-mannose, an adjuvant in the non-viral gene therapeutic formulation. This review will include gene therapeutic approaches showing the most promise in controlling pro-inflammatory signaling via increased expression of anti-inflammatory cytokines like interleukin-10 (IL-10) or IL-4, or by directly limiting the bioavailability of specific pro-inflammatory cytokines, as with tumor necrosis factor (TNF) by the TNF soluble receptor (TNFSR). Approaches that increase endogenous anti-inflammatory signaling may offer additional opportunities for pain therapeutic development in patients not candidates for gene therapy. Promising novel avenues discussed here include the disruption of lymphocyte function-associated antigen (LFA-1) activity, antagonism at the cannabinoid 2 receptor (CB2R), and toll-like receptor 4 (TLR4) antagonism. Given the partial efficacy of current drugs, new strategies to manipulate neuroimmune and cytokine interactions hold considerable promise.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pattern Recognition Receptors and Inflammation
Takeuchi, O., & Akira, S. (2010) · Cell · doi:10.1016/j.cell.2010.01.022 · Cited by 8,895
Vos, T., Allen, C., Arora, M., Barber, R. M., Bhutta, Z. A., Brown, A., Carter, A., Casey, D. C., Charlson, F. J., Chen, A. Z., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31678-6 · Cited by 7,253
Interleukin-10 and the Interleukin-10 Receptor
Moore, K. W., de Waal Malefyt, R., Coffman, R. L., & O'Garra, A. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.683 · Cited by 6,737 · cited 4×
“Additionally, TNF-α and IL-1β enhance excitatory AMPAand NMDA-induced currents, and IL-1β and IL-6 suppress inhibitory GABA- and glycine-induced currents (39).”
BackgroundInfluentialAlternative activation of macrophages
Gordon, S. (2003) · Nature Reviews Immunology · doi:10.1038/nri978 · Cited by 6,189
Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735 · cited 1×
“To date, there are three FDA approved gene therapies, including Spinraza (nusinersen; anti-sense oligonucleotide for treatment of spinal muscular atrophy type 1) (64, 65), Kymriah (tisagenlecleucel; CAR T-cell therapy for treatment of B-cell precursor acute lymphoblastic leukemia) (66), and Luxturna (voretigene neparv…”
BackgroundCentral sensitization: a generator of pain hypersensitivity by central neural plasticity
Latremoliere, A., & Woolf, C. J. (2009) · The Journal of Pain · doi:10.1016/j.jpain.2009.06.012 · Cited by 3,913
Treede, R.-D., Rief, W., Barke, A., Aziz, Q., Bennett, M. I., Benoliel, R., Cohen, M., Evers, S., Finnerup, N. B., First, M. B., et al. (2019) · Pain · doi:10.1097/j.pain.0000000000001384 · Cited by 3,478
Non-viral vectors for gene-based therapy
Yin, H., Kanasty, R. L., Eltoukhy, A. A., Vegas, A. J., Dorkin, J. R., & Anderson, D. G. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3763 · Cited by 3,123 · cited 1×
“, plasmid DNA) from degradation by endonucleases, targeting to the therapy to cells of interest, as well as promoting cellular entry (73).”
BackgroundNusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy
Finkel, R. S., Mercuri, E., Darras, B. T., Connolly, A. M., Kuntz, N. L., Kirschner, J., Chiriboga, C. A., Saito, K., Servais, L., Tizzano, E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1702752 · Cited by 2,337 · cited 1×
“To date, there are three FDA approved gene therapies, including Spinraza (nusinersen; anti-sense oligonucleotide for treatment of spinal muscular atrophy type 1) (64, 65), Kymriah (tisagenlecleucel; CAR T-cell therapy for treatment of B-cell precursor acute lymphoblastic leukemia) (66), and Luxturna (voretigene neparv…”
BackgroundEvidence for a central component of post-injury pain hypersensitivity
Woolf, C. J. (1983) · Nature · doi:10.1038/306686a0 · Cited by 2,157 · cited 1×
“This enhanced signaling within the dorsal horn further sensitizes second order sensory neurons through a mechanism known as central sensitization, a neurobiological plasticity process first characterized by Woolf in the early 1980s (18).”
BackgroundRussell, S., Bennett, J., Wellman, J. A., Chung, D. C., Yu, Z.-F., Tillman, A., Wittes, J., Pappas, J., Elci, O., McCague, S., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31868-8 · Cited by 1,952
New tools for studying microglia in the mouse and human CNS
Bennett, M. L., Bennett, F. C., Liddelow, S. A., Ajami, B., Zamanian, J. L., Fernhoff, N. B., Mulinyawe, S. B., Bohlen, C. J., Adil, A., Tucker, A., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1525528113 · Cited by 1,804
SOCS proteins, cytokine signalling and immune regulation
Yoshimura, A., Naka, T., & Kubo, M. (2007) · Nature Reviews Immunology · doi:10.1038/nri2093 · Cited by 1,580 · cited 1×
“IL-10 signaling also induces suppressor of cytokine signaling 1 (SOCS1) and SOCS3 production, thereby further suppressing pro-inflammatory cytokine production by targeting the p65 NF-κB subunit (a key transcriptional regulator in the inflammatory process) for degradation (124).”
BackgroundDifferent immune cells mediate mechanical pain hypersensitivity in male and female mice
Sorge, R. E., Mapplebeck, J. C. S., Rosen, S., Beggs, S., Taves, S., Alexander, J. K., Martin, L. J., Austin, J.-S., Sotocinal, S. G., Chen, D., et al. (2015) · Nature Neuroscience · doi:10.1038/nn.4053 · Cited by 1,442
Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy
Mercuri, E., Darras, B. T., Chiriboga, C. A., Day, J. W., Campbell, C., Connolly, A. M., Iannaccone, S. T., Kirschner, J., Kuntz, N. L., Saito, K., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1710504 · Cited by 1,433 · cited 1×
“To date, there are three FDA approved gene therapies, including Spinraza (nusinersen; anti-sense oligonucleotide for treatment of spinal muscular atrophy type 1) (64, 65), Kymriah (tisagenlecleucel; CAR T-cell therapy for treatment of B-cell precursor acute lymphoblastic leukemia) (66), and Luxturna (voretigene neparv…”
BackgroundDunbar, C. E., High, K. A., Joung, J. K., Kohn, D. B., Ozawa, K., & Sadelain, M. (2018) · Science · doi:10.1126/science.aan4672 · Cited by 1,410
Alveolar macrophages: plasticity in a tissue-specific context
Hussell, T., & Bell, T. J. (2014) · Nature Reviews Immunology · doi:10.1038/nri3600 · Cited by 1,377 · cited 1×
“capable of increasing anti-inflammatory cytokines under the right conditions (144, 153).”
BackgroundPain regulation by non-neuronal cells and inflammation
Ji, R.-R., Chamessian, A., & Zhang, Y.-Q. (2016) · Science · doi:10.1126/science.aaf8924 · Cited by 1,314 · cited 1×
“For example, the pro-inflammatory cytokines TNFα and IL-1β enhance excitatory synaptic transmission and suppress inhibitory synaptic transmission in neurons of spinal cord lamina II (31, 39).”
BackgroundInterferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion
Castro, F., Cardoso, A. P., Gonçalves, R. M., Serre, K., & Oliveira, M. J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00847 · Cited by 1,224
Opioid-induced Hyperalgesia: A Qualitative Systematic Review
Angst, M. S., & Clark, J. D. (2006) · Anesthesiology · doi:10.1097/00000542-200603000-00025 · Cited by 1,188
Kawasaki, Y., Zhang, L., Cheng, J.-K., & Ji, R.-R. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.3338-07.2008 · Cited by 1,162
Sabat, R., Grütz, G., Warszawska, K., Kirsch, S., Witte, E., Wolk, K., & Geginat, J. (2010) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2010.09.002 · Cited by 977 · cited 1×
“phosphorylation as well as increased nuclear translocation and DNA binding of p50/p50 homodimers of NF-κB, a form of NF-κB insufficient for induction of pro-inflammatory cytokine transcription (129).”
BackgroundLoss of ‘homeostatic’ microglia and patterns of their activation in active multiple sclerosis
Zrzavy, T., Hametner, S., Wimmer, I., Butovsky, O., Weiner, H. L., & Lassmann, H. (2017) · Brain · doi:10.1093/brain/awx113 · Cited by 684
The CNS role of Toll-like receptor 4 in innate neuroimmunity and painful neuropathy
Tanga, F. Y., Nutile-McMenemy, N., & DeLeo, J. A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501634102 · Cited by 634 · cited 1×
“The anti-inflammatory effects of IL-10 come about by blocking downstream signaling of TLR4, the actions of which normally promote a pro-inflammatory environment critical for the development of neuropathic pain (125).”
BackgroundIL-4 in the brain: a cytokine to remember
Gadani, S. P., Cronk, J. C., Norris, G. T., & Kipnis, J. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1202246 · Cited by 549
TMEM119 marks a subset of microglia in the human brain
Satoh, J., Kino, Y., Asahina, N., Takitani, M., Miyoshi, J., Ishida, T., & Saito, Y. (2016) · Neuropathology · doi:10.1111/neup.12235 · Cited by 434
Brain microglia constitutively express β-2 integrins
Akiyama, H., & McGeer, P. L. (1990) · Journal of Neuroimmunology · doi:10.1016/0165-5728(90)90055-r · Cited by 430
Zhuang, Z.-Y., Kawasaki, Y., Tan, P.-H., Wen, Y.-R., Huang, J., & Ji, R.-R. (2007) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2006.11.003 · Cited by 371
The mannose receptor: linking homeostasis and immunity through sugar recognition
TAYLOR, P., GORDON, S., & MARTINEZPOMARES, L. (2005) · Trends in Immunology · doi:10.1016/j.it.2004.12.001 · Cited by 368
Immune Responses to AAV in Clinical Trials
Mingozzi, F., & A. High, K. (2011) · Current Gene Therapy · doi:10.2174/156652311796150354 · Cited by 324
Sex differences in neuroimmunity and pain
Rosen, S., Ham, B., & Mogil, J. S. (2017) · Journal of Neuroscience Research · doi:10.1002/jnr.23831 · Cited by 318
Cannabinoids as Pharmacotherapies for Neuropathic Pain: From the Bench to the Bedside
Rahn, E. J., & Hohmann, A. G. (2009) · Neurotherapeutics · doi:10.1016/j.nurt.2009.08.002 · Cited by 305
Hyperalgesic responses in methadone maintenance patients
Doverty, M., White, J. M., Somogyi, A. A., Bochner, F., Ali, R., & Ling, W. (2001) · Pain · doi:10.1016/s0304-3959(00)00391-2 · Cited by 297
Staton, P. C., Hatcher, J. P., Walker, D. J., Morrison, A. D., Shapland, E. M., Hughes, J. P., Chong, E., Mander, P. K., Green, P. J., Billinton, A., et al. (2008) · Pain · doi:10.1016/j.pain.2008.04.006 · Cited by 270
Echeverry, S., Shi, X. Q., & Zhang, J. (2008) · Pain · doi:10.1016/j.pain.2007.05.002 · Cited by 211 · cited 1×
“complement receptor 3 (CR3), cluster of differentiation 11b (CD11b), or ionized calcium binding adaptor molecule 1 (Iba1) (8, 23, 24).”
BackgroundTargeting cytokines for treatment of neuropathic pain
Hung, A. L., Lim, M., & Doshi, T. L. (2017) · Scandinavian Journal of Pain · doi:10.1016/j.sjpain.2017.08.002 · Cited by 174 · cited 2×
“TNF soluble receptor (TNFSR), commercially known as etanercept, is previously approved by the FDA for treatment of painful inflammatory conditions including rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis (109).”
BackgroundRomero-Sandoval, A., Nutile-McMenemy, N., & DeLeo, J. A. (2008) · Anesthesiology · doi:10.1097/aln.0b013e318167af74 · Cited by 168
Rahn, E. J., Makriyannis, A., & Hohmann, A. G. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707333 · Cited by 146
Rahn, E. J., Zvonok, A. M., Thakur, G. A., Khanolkar, A. D., Makriyannis, A., & Hohmann, A. G. (2008) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.141994 · Cited by 116
Lindenlaub, T., Teuteberg, P., Hartung, T., & Sommer, C. (2000) · Brain Research · doi:10.1016/s0006-8993(00)02190-9 · Cited by 102
Deng, L., Guindon, J., Vemuri, V. K., Thakur, G. A., White, F. A., Makriyannis, A., & Hohmann, A. G. (2012) · Molecular Pain · doi:10.1186/1744-8069-8-71 · Cited by 94
Non-viral strategies for ocular gene delivery
Oliveira, A. V., Rosa da Costa, A. M., & Silva, G. A. (2017) · Materials Science and Engineering: C · doi:10.1016/j.msec.2017.04.068 · Cited by 80 · cited 1×
“To ameliorate the dose limitations, various carriers for non-viral gene therapy have been explored but are limited by adverse effects or added levels of complexity (71, 72, 141).”
Background
Cited by
Central Nervous System Targets: Glial Cell Mechanisms in Chronic Pain
Donnelly, C. R., Andriessen, A. S., Chen, G., Wang, K., Jiang, C., Maixner, W., & Ji, R.-R. (2020) · Neurotherapeutics · doi:10.1007/s13311-020-00905-7 · Cited by 301
Metadata
- Authors
- Vanderwall, A. G., & Milligan, E. D.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2019-12-23
- Volume
- 10
- Pages
- 3009-3009
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W2998373951
- Cited by
- 218
- References
- 42
- FWCI
- 10.86
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.